Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gillette lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Gillette's proposed merger with Procter & Gamble is "unduly favorable" to P&G, company shareholders maintain in a putative class action lawsuit filed in Delaware state court Feb. 10. The suit alleges breaches of fiduciary duties by Gillette's board of directors and senior management regarding the proposed merger, and claims P&G senior management will receive "excessive compensation" as a result of the deal. The plaintiffs seek injunctive relief halting consummation of the merger or rescission following its consummation, as well as compensatory damages. A similar suit was filed in Delaware state court the following day, and a motion to consolidate the two is pending. P&G and Gillette said they find the allegations to be without merit. Massachusetts state regulators are investigating the deal based on Gillette CEO James Kilts' substantial compensation package (1"The Tan Sheet" Feb. 7, 2005, p. 9)...

You may also be interested in...

State Regulators Understood To Be Eyeing Gillette CEO Package In P&G Deal

The compensation package for Gillette CEO James Kilts outlined under terms of the merger with Procter & Gamble reportedly has drawn the attention of regulatory investigators

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts